期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 60, 期 5, 页码 3163-3169出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.03042-15
关键词
-
资金
- AstraZeneca Pharmaceuticals as part of the INFORM global surveillance program
The activity of ceftazidime-avibactam was assessed against 961 isolates of meropenem-nonsusceptible Enterobacteriaceae. Most meropenem-nonsusceptible metallo-beta-lactamase (MBL)-negative isolates (97.7%) were susceptible to ceftazidime-avibactam. Isolates that carried KPC or OXA-48-like beta-lactamases, both alone and in combination with extended-spectrum beta-lactamases (ESBLs) and/or AmpC beta-lactamases, were 98.7% and 98.5% susceptible to ceftazidime-avibactam, respectively. Meropenem-nonsusceptible, carbapenemase-negative isolates demonstrated 94.7% susceptibility to ceftazidime-avibactam. Ceftazidime-avibactam activity was compromised only in isolates for which carbapenem resistance was mediated through metallo-beta-lactamases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据